Announcements Trials
Browse Landscape

Status

Completed 5No longer available 2Available 2Approved for marketing 2Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Expanded_access 2

Sponsor

Cancer Type

Endocrine 2CNS 2

Conditions

Pheochromocytoma 2Neuroblastoma 2Paraganglioma 1

Interventions

3-Iodobenzylguanidine 2pegfilgrastim 1fluorodopa F 18 1Vorinostat 1Potassium Iodide 1Granulocyte Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
No longer available × Pheochromocytoma × 3-Iodobenzylguanidine × Clear all
NCT03649438 2024-12-11

131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Relapsed/Refractory Neuroblastoma

University of Texas Southwestern Medical Center

No longer available
CNSEndocrine

Neuroblastoma, Pheochromocytoma

NCT01838187 2023-08-18

Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma

Children's Hospital Medical Center, Cincinnati

No longer available
CNSEndocrine

Neuroblastoma, Paraganglioma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡